VIM and gastric cancer: These biomarkers include ADAM17 (Shou et al., 2012), MMP2, MMP9, and MMP11 (Sampieri et al., 2010; Zhao et al., 2010), survivin and CK19 (Bertazza et al., 2009), vimentin (Iwatsuki et al., 2010), CXCR4 (Ingold et al., 2010), ING5 (Xing et al., 2011), and Stanniocalcin2 (Yokobori et al., 2010); in all of these examples, these molecules are overexpressed in tumoral GC tissues.